Background Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic‐
associated diarrhoea and colitis. This review is an update of a previously published …

Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI)
have been updated. However, in addition to the clinical efficacy data, the drug of choice …

Toxigenic culture and cytotoxicity assays are standard tests for detecting C. difficile infection
(CDI). Others include immunochromatographic strips, a rapid diagnostic test that detects …

Background Decreases in clinical response of Clostridioides difficile to antibiotics used for
its treatment have raised concerns regarding antibiotic resistance. We conducted a …

Objectives To describe, for the first time (to the best of our knowledge), the genetic
mechanisms of vancomycin resistance in clinical isolates of Clostridioides difficile ribotype …

Fulminant Clostridioides difficile infection (FCDI) encompasses 3 to 5% of all CDI cases with
associated mortality rates between 30 and 40%. Major treatment modalities include surgery …

Objectives Teicoplanin is a potential antimicrobial candidate for Clostridioides difficile
infection (CDI) treatment. However, the therapeutic potential of teicoplanin against severe …

At present, vancomycin (VCM) and metronidazole (MNZ) are used for the first-line standard
treatment of Clostridioides difficile infection (CDI). However, their differential use has not …

Background Limited data currently exist on the incidence of Clostridioides difficile infection
(CDI) in Saudi Arabia. Compliance with CDI treatment guidelines is prudent for proper …

Live biotherapeutic products (LBPs) are human microbiome therapies showing promise in
the clinic for a range of diseases and conditions. Describing the kinetics and behavior of …